We are live on
!
Find out more
OMC
OUP Management Company Portfolio holdings
AUM
$44.5M
1-Year Est. Return
55.11%
This Fund
S&P 500
This Quarter
Est. Return
+21.9%
1 Year Est. Return
+55.11%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$61.3M
AUM Growth
-$2.96M
(-4.6%)
Cap. Flow
-$8.76M
Cap. Flow
% of AUM
-14.31%
Top 10 Holdings %
Top 10 Hldgs %
96.86%
Holding
16
New
1
Increased
–
Reduced
2
Closed
2
Avg Time Held
3.7
quarters
Top 10 Avg Time Held
3
quarters
Top 20 Avg Time Held
3.7
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Prime Medicine
PRME
|
+$2.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DICE Therapeutics, Inc. Common Stock
DICE
|
+$8.75M |
| 2 |
Evolv Technologies
EVLV
|
+$1.38M |
| 3 |
Landos Biopharma, Inc. Common Stock
LABP
|
+$804K |
| 4 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
+$16K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.37% |
| 2 | Technology | 6.63% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Jade Biosciences
JBIO
$892M
| $17.7M | 28.88% |
17,250
| – | – |
2021 Q4
4 quarters
|
|
|
CNTA
2
DELISTED
Centessa Pharmaceuticals
CNTA
| $9.11M | 14.87% |
2,937,615
| – | – |
2021 Q4
4 quarters
|
|
3
PMV Pharmaceuticals
PMVP
$79.1M
| $8.61M | 14.05% |
989,232
| – | – |
2021 Q4
4 quarters
|
|
|
4
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $8.37M | 13.67% |
268,346
-268,347
| -50% | -$8.75M |
2021 Q4
4 quarters
|
|
5
IonQ
IONQ
$14.6B
| $4.06M | 6.63% |
1,177,597
| – | – |
2021 Q4
4 quarters
|
|
|
CYT
6
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $4.06M | 6.63% |
2,459,572
-10,000
| -0.4% | -$16K |
2021 Q4
4 quarters
|
|
7
Vor Biopharma
VOR
$1.19B
| $2.49M | 4.07% |
18,736
| – | – |
2021 Q4
4 quarters
|
|
|
8
Prime Medicine
PRME
$657M
| $2.25M | 3.68% |
+121,255
| New | +$2.19M |
2022 Q4
0 quarters
|
|
9
LENZ Therapeutics
LENZ
$115M
| $1.35M | 2.2% |
58,044
| – | – |
2021 Q4
4 quarters
|
|
10
Precision BioSciences
DTIL
$178M
| $1.34M | 2.18% |
37,464
| – | – |
2021 Q4
4 quarters
|
|
11
Cartesian Therapeutics
RNAC
$213M
| $975K | 1.59% |
28,751
| – | – |
2021 Q4
4 quarters
|
|
12
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| $439K | 0.72% |
41,028
| – | – |
2021 Q4
4 quarters
|
|
13
Spero Therapeutics
SPRO
$69.9M
| $431K | 0.7% |
249,070
| – | – |
2021 Q4
4 quarters
|
|
14
Q32 Bio
QTTB
$263M
| $80.6K | 0.13% |
3,556
| – | – |
2021 Q4
4 quarters
|
|
|
15
Evolv Technologies
EVLV
$792M
| – | – |
-652,475
| Closed | -$1.38M | – |
|
|
16
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
| – | – |
-123,767
| Closed | -$804K | – |
|
Similar funds
JMF
AMC
MCAV
SIP
KXA
WRCAI
MAM
GIA
OUP Management Company's Q4 2022 Portfolio in Review
As of Q4 2022, OUP Management Company held 16 positions worth $61.3M, down 4.6% from $64.2M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
OUP Management Company withdrew a net $8.76M in Q4 2022, closing 2 positions and reducing 2 holdings. Its most notable exit was Evolv Technologies, an estimated $1.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Technology and Industrials.
Against the trend, OUP Management Company opened a new position in Prime Medicine worth $2.25M.
- OUP Management Company's largest Q4 2022 buy was Prime Medicine: 121,255 shares worth $2.25M.
- OUP Management Company's biggest Q4 2022 reduction was DICE Therapeutics, Inc. Common Stock, cutting an estimated $8.75M.
- OUP Management Company fully exited Evolv Technologies in Q4 2022, selling an estimated $1.38M.
- OUP Management Company's ten largest holdings make up 97% of its $61.3M portfolio in Q4 2022.
- OUP Management Company opened 1 new position and closed 2 in Q4 2022.
- OUP Management Company's portfolio value fell 4.6% quarter-over-quarter to $61.3M.
Based on OUP Management Company's 13F filing for Q4 2022, filed 2 Feb 2023.